Undercarboxylated osteocalcin (ucOC) improves glucose metabolism; however, its effects on endothelial cell function are unclear. We examined the biological effect of ucOC on endothelial function in animal models ex vivo and human cells in vitro. Isometric tension and immunohistochemistry techniques were used on the aorta of male New Zealand white rabbits and cell culture techniques were used on human aortic endothelial cells (HAECs) to assess the effect of ucOC in normal and high‐glucose environments. Overall, ucOC, both 10 and 30 ng/ml, did not significantly alter acetylcholine‐induced blood vessel relaxation in rabbits (p > .05). UcOC treatment did not cause any significant changes in the immunoreactivity of cellular signalling markers (p > .05). In HAEC, ucOC did not change any of the assessed outcomes (p > .05). UcOC has no negative effects on endothelial function which is important to reduce the risks of off target adverse effects if it will be used as a therapeutic option for metabolic disease in the future.

中文翻译：

---

低羧化骨钙素对兔主动脉或人血管细胞的内皮功能无不良影响

低羧化骨钙素 (ucOC) 改善葡萄糖代谢；然而，其对内皮细胞功能的影响尚不清楚。我们在体外动物模型和体外人类细胞中检查了 ucOC 对内皮功能的生物学影响。等长张力和免疫组织化学技术用于新西兰雄性白兔的主动脉，细胞培养技术用于人主动脉内皮细胞（HAEC），以评估 ucOC 在正常和高糖环境中的作用。总体而言，10 和 30 ng/ml 的 ucOC 没有显着改变兔乙酰胆碱诱导的血管松弛 ( p  > .05)。UcOC 治疗并未引起细胞信号标志物免疫反应性的任何显着变化（p > .05）。在 HAEC 中，ucOC 没有改变任何评估结果 ( p  > .05)。UcOC 对内皮功能没有负面影响，如果将来将其用作代谢疾病的治疗选择，这对于降低脱靶不良反应的风险很重要。